FABP-1 and Its Link to Pancreatic Cancer and Diabetes
Author Information
Author(s): Sharaf Ravi N, Butte Atul J, Montgomery Kelli D, Pai Reetesh, Dudley Joel T, Pasricha Pankaj J
Primary Institution: Stanford University School of Medicine
Hypothesis
The study aimed to validate the association between FABP-1 and pancreatic adenocarcinoma, particularly in patients with diabetes.
Conclusion
There is a significant positive association between FABP-1 staining and pancreatic adenocarcinoma, especially in the presence of diabetes.
Supporting Evidence
- FABP-1 staining was significantly associated with the diagnosis of pancreatic adenocarcinoma.
- Diabetic pancreatic adenocarcinoma samples showed increased FABP-1 staining compared to normal samples.
- The study identified FABP-1 as a potential biomarker for pancreatic cancer and diabetes.
Takeaway
Researchers found that a protein called FABP-1 is more common in pancreatic cancer, especially in people who also have diabetes.
Methodology
The study used tissue microarrays and immunohistochemistry to analyze FABP-1 staining in pancreatic tissue samples.
Potential Biases
Selection bias may have influenced the results due to the nonrandom sample collection.
Limitations
The study had a small sample size and was retrospective, which may affect the generalizability of the findings.
Participant Demographics
The sample included 134 patients, with a mix of ages and a history of diabetes, tobacco, and alcohol use.
Statistical Information
P-Value
0.004
Confidence Interval
95% CI 1.1-68
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website